Friday, September 28, 2018
Piper says Alnylam making transition to commercial play on orphan diseases
After Alnylam announced an NDA filing on Onpattro for hATTR Amyloidosis in Japan, Piper Jaffray analyst Edward Tenthoff said the company is transitioning toward being a commercial play on orphan diseases. The analyst, who forecasts 2018 Onpattro sales of $10.7M growing to $81M in 2019, keeps an Overweight and $160 price target on Alnylam shares.
https://thefly.com/landingPageNews.php?id=2797205
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.